Iovance Biotherapeutics I... (IOVA)

Experienced investors understand that being in the stock market requires a long-term, multiyear mindset. For truly patient people though, the reward is well worth the wait; you'd be hard-pressed to fi...

Investors are typically quite harsh on publicly traded companies that don't make their quarterly estimates, a dynamic vividly on display Friday with biotech stock Iovance Biotherapeutics (IOVA -20.08%...

Iovance shares plunge after Q2 miss and voluntary withdrawal of Amtagvi's EU filing, despite strong U.S. sales growth for the therapy.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Daniel G. Kirby - Chief Commercial Officer Frederick G.

Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.34 per share a year ago.

Iovance (IOVA) Q2 Revenue Jumps 93%

Shares of Iovance Biotherapeutics (IOVA -1.02%) have been in a free fall this past year, but in recent weeks, they have experienced a bit of a surge in value. The volatile biotech stock has been picki...

Shares of Iovance Biotherapeutics (IOVA -5.91%) are down about 75% from a high-water mark they set last December. Up and down Wall Street, investment bank analysts tasked with following the commercial...

Iova stock rallied 32% on Wednesday, snapping out of a long, sluggish stretch that had frustrated investors for months. The Iovance Biotherapeutics (NASDAQ: IOVA) shares have been stuck in a tight ran...

Iovance Biotherapeutics, Inc. stock is down nearly 30% since my "sell" recommendation in April. Q1 earnings disappointed, with Amtagvi sales underperforming the Street's expectations and guidance revi...